Chemical Data :
IUPAC: 1-Pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester
Molecular Weight: 342.846
Molecular Formula: C23H22N2O2
PB-22, otherwise known as QUPIC, is a synthetic cannabinoid of the indole class.
It has only come to light since being detected in synthetic cannabis in Japan in 2013.
Like other members of the indole and indazole class of synthetic cannabinoids, PB-22 is a highly potent full agonist at human cannabinoid receptor CB1.
It has an EC50 of 5.1 nM at CB1 and 37 nM at CB2. It has been shown to produce significant hypothermia and bradycardia in rats at doses of 0.3-3 mg/ kg. Notably, the duration and strength of the hypothermia induced by PB-22 in rats was greater than comparable synthetic cannabinoids JWH-018, AM-2201, XLR-11, STS-135, UR-144 and APICA. Reduced body temperature was recorded up to six hours after administration of the dose.
In 2014 a 22 year old man and his dog both suffered seizures after consuming PB-22 as part of a synthetic cannabis mixture called “crazy monkey”. 3 months later after still continuing to use the drug he was admitted to hospital once more and had to be intubated and treated for seizures.
It is the full agonist action and extreme potency of the indole and indazole cannabinoids which makes them so potentially harmful. THC, the primary psychoactive constituent of cannabis, is only a partial agonist at CB1. As a result, it is a much safer drug, with no recorded deaths from use and no real danger presented by overdose. The synthetic cannabinoids, by contrast, are active at 1 mg or less – an amount often difficult to measure. Furthermore, if consumed to overdose, these compounds are potentially lethal. There are many well documented cases of seizures and deaths resulting from consumption of synthetic cannabinoids.
The health effects of long term or short term recreational use of PB-22 are not known. Its toxicological profile has not been studied. It is one of a plethora of new synthetic cannabinoids for which there is a dearth or reliable information.
PB-22 is not fit for human or animal consumption.
Unverifiable online reports can give us some insight in to the effects of this potent drug compound.
Users have reported a highly sedating component to the experience, with a strong body high that may become overwhelming. Additionally there are reports of loss of motor control, pain relief, increased heart rate and dehydration.
Like other cannabinoids, PB-22 is said to enhance the emotional state of the user. This can produce experiences ranging from euphoria to paranoia, agitation and anxiety. Some users report feelings of dissociation from their bodies and depersonalisation.
PB-22 may induce dizziness, nausea and vomiting, especially in combination with alcohol.
Cannabinoids are associates with exacerbation of underlying mental health conditions such as anxiety and schizophrenia. For this reason they may be particularly hazardous for young adults and adolescents.
Adverse side effects are much more likely to manifest with continuous use or use at high doses.
PB-22 is likely to be an addictive substance with a high potential for abuse. There are reports of uncomfortable withdrawal effects after heavy and continual use.
Other names and synonyms